Jeffrey S. Hackman's most recent trade in Fennec Pharmaceuticals Inc was a trade of 13,710 Common Shares done . Disclosure was reported to the exchange on Feb. 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fennec Pharma Inc | Jeffrey S. Hackman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 13,710 | 28,710 (0%) | 0% | 0 | Common Shares | |
| Fennec Pharma Inc | Jeffrey S. Hackman | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 6.99 per share. | 16 May 2025 | 13,965 | 15,000 (0%) | 0% | 7.0 | 97,615 | Common Shares |
| Fennec Pharma Inc | Jeffrey S. Hackman | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 6.75 per share. | 16 May 2025 | 1,035 | 1,035 (0%) | 0% | 6.7 | 6,986 | Common Shares |
| Fennec Pharma Inc | Jeffrey S. Hackman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2025 | 75,000 | 475,000 | - | - | Restricted Share Unit | |
| Fennec Pharma Inc | Jeffrey S. Hackman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2025 | 50,000 | 525,000 | - | - | Stock Options | |
| Fennec Pharma Inc | Jeffrey S. Hackman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 400,000 | 400,000 | - | - | Stock Options | |
| Comera Life Sciences Holdings | Jeffrey S. Hackman | Director, See Remarks. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Purchase) | |
| Comera Life Sciences Holdings | Jeffrey S. Hackman | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 2.06 per share. | 09 Sep 2022 | 47,600 | 47,600 | - | 2.1 | 98,056 | Common Stock |
| Comera Life Sciences Holdings | Jeffrey S. Hackman | Director, See Remarks. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2022 | 300,000 | 300,000 | - | - | Stock Option (Right to Purchase) |